GlassScriptPhysician profile
Jay V Malickel
NPI 1902893134
$1,731.43
in general payments reported to CMS, 2019-2025
19 companies · $89.06 in 2025
The $89.06 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $316 · 2020: $98.71 · 2022: $127 · 2023: $641 · 2024: $460 · 2025: $89.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,189.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $299.97 | 2019-2024 | Rybelsus, Ozempic |
| Abbvie INC. | $285.23 | 2022-2025 | |
| Glaxosmithkline, LLC. | $241.59 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $180.99 | 2022-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.88 | 2019-2024 | Jardiance, Tradjenta |
| Astellas Pharma US INC | $123.30 | 2023-2025 | Veozah |
| Abbott Laboratories | $98.24 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $88.23 | 2019-2023 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $49.07 | 2019-2020 | |
| Pfizer INC. | $43.55 | 2019-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $37.10 | 2022 | |
| Merck Sharp & Dohme LLC | $34.34 | 2019 | |
| Sanofi-Aventis U.S. LLC | $34.22 | 2023 | |
| Exact Sciences Corporation | $21.60 | 2024 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $15.59 | 2023 | Injectafer |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $14.86 | 2023 | Minimed 770g |
| Janssen Pharmaceuticals, INC | $13.79 | 2019 | |
| Esperion Therapeutics, INC. | $13.48 | 2024 | Nexletol |
| Amarin Pharma, INC. | $11.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Malickel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.